02575.HK
Xuanzhubio-b
HKSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
HKD 10.43
−6.21%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−20.3x
Market Cap
HKD 4.70B
MomentumView details →
1D Return
−6.21%
YTD Return
−85.21%
RSI (14)
42.3
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−20.3x
Market Cap
HKD 4.70B
RSI (14)
42.3
MomentumView details →
1D Return
−6.21%
YTD Return
−85.21%
Similar companies
Latest newsMore news →
Xuanzhu Biopharmaceutical signed a tripartite commercial agreement with Innobic (Asia) and ZaoAn International to grant exclusive commercialization rights for Piroxiclib tablets in Thailand, effective until June 30, 2036.2d agoXuanzhu Biopharmaceutical reported interim results for the six months ended June 2026, with revenue of RMB 69.441 million, up 288.1% year-on-year, and a narrowed net loss of RMB 75.34 million.10d ago